Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Yartemlea Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.06.29

    Yartemlea (narsoplimab-wuug) Coverage for Transplant-Associated Thrombotic Microangiopathy

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.06.29 alerts

    Get alerted when Policy 05.06.29 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity criteria for Yartemlea (narsoplimab-wuug) used to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). It applies to members whose benefits include the therapy and who meet the initial or continuation criteria.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyYartemlea (narsoplimab-wuug) Coverage for Transplant-Associated Thrombotic Microangiopathy
    Policy CodePolicy 05.06.29
    Change TypeNo material change
    Effective DateMay 15, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization documentation confirming TA-TMA and ADAMTS13 activity for initial requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsInitial authorization period
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Continuation authorization period
    Age ≥ 2Minimum age for initial approval
    <150,000/µLPlatelet-count criterion
    ≥10%Required ADAMTS13 activity

    Coverage Criteria

    Initial Therapy Criteria

    Covered for 6 months when all of the following criteria are met.

    Initial therapy for TA-TMA

    • Age: The member is 2 years of age or older.≥ 2 years
    • TA-TMA laboratory confirmation: The diagnosis is confirmed by a platelet count below 150,000/µL and evidence of microangiopathic hemolysis, including the presence of schistocytes, serum LDH greater than the upper limit of normal (ULN), and/or haptoglobin less than the lower limit of normal (LLN).Platelets < 150,000/µL
    • ADAMTS13 activity: The member has an ADAMTS13 activity level of at least 10%.≥ 10%
    • Prohibited combination therapy: The requested medication will not be used in combination with another complement inhibitor, such as Soliris or Ultomiris, or with Defitelio (defibrotide).

    Continuation Therapy Criteria

    Covered for 12 months, including new members, when all of the following criteria are met.

    Continuation therapy for TA-TMA

    • Tolerability: There is no unacceptable toxicity while the member is on the current regimen.
    • Clinical response: The member demonstrates a positive response to therapy, such as improvement in platelet levels or normalization of lactate dehydrogenase (LDH) and haptoglobin levels.
    • Prohibited combination therapy: The requested medication will not be used in combination with another complement inhibitor, such as Soliris or Ultomiris, or with Defitelio (defibrotide).

    Combination therapy exclusion: Yartemlea (narsoplimab-wuug) is not approved for use in combination with another complement inhibitor, including Soliris or Ultomiris, or with Defitelio (defibrotide). This exclusion applies to both initial and continued treatment requests.

    Yartemlea is considered not medically necessary when the member does not meet the applicable initial or continuation coverage criteria.

    Initial Therapy Criteria

    TA-TMA Initial Approval

    Authorization of 6 months may be granted for treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) when all of the following criteria are met.

    TA-TMA initial approval

    • Age: The member is 2 years of age or older.≥ 2 years
    • TA-TMA laboratory confirmation: The diagnosis is confirmed by a platelet count below 150,000/µL and evidence of microangiopathic hemolysis, including the presence of schistocytes, serum LDH greater than the upper limit of normal (ULN), and/or haptoglobin less than the lower limit of normal (LLN).Platelets < 150,000/µL
    • ADAMTS13 activity:

    Continuation Criteria

    TA-TMA Continuation

    Authorization of 12 months, including new members, may be granted for continued treatment when all of the following criteria are met.

    TA-TMA continuation

    • Tolerability: There is no unacceptable toxicity while the member is on the current regimen.
    • Clinical response: The member demonstrates a positive response to therapy, such as improvement in platelet levels or normalization of lactate dehydrogenase (LDH) and haptoglobin levels.
    • Prohibited combination therapy: The requested medication will not be used in combination with another complement inhibitor, such as Soliris or Ultomiris, or with Defitelio (defibrotide).

    Coding Information

    Narsoplimab-wuug codeHCPCS
    J1289Injection, narsoplimab-wuug, 1 mg (effective 7/1/26)
    Unclassified drug and biologic codesHCPCS
    J3490unclassified drugs
    J3590unclassified biologics
    C9399unclassified drugs or biologicals
    Platelet Count
    ThresholdPlatelet count < 150,000/µL
    Clinical useRequired to confirm hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
    Associated findingMust be accompanied by evidence of microangiopathic hemolysis.
    ADAMTS13 Activity
    ThresholdADAMTS13 activity level ≥ 10%
    RequirementLaboratory activity measurement required for initial approval.
    Coverage context

    Prior Authorization and Provider Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial Yartemlea treatment of transplant-associated thrombotic microangiopathy (TA-TMA). Submit documentation confirming the diagnosis and required laboratory findings.

    • Member is 2 years of age or older.
    • TA-TMA is confirmed by a platelet count < 150,000/µL and evidence of microangiopathic hemolysis, including schistocytes, serum LDH greater than the ULN and/or haptoglobin less than the LLN.
    • ADAMTS13 activity is ≥ 10%.
    • Yartemlea will not be used with another complement inhibitor, such as Soliris or Ultomiris, or with Defitelio (defibrotide).
    Prior Authorization

    Continuation Prior Authorization Required

    Prior authorization is required for continuation or reauthorization of Yartemlea. Continued treatment requires documentation of clinical benefit, tolerability, and compliance with prohibited-combination restrictions.

    Policy Background

    Yartemlea (narsoplimab-wuug) is covered for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Initial coverage requires laboratory findings consistent with TA-TMA, including a platelet count below 150,000/µL and evidence of microangiopathic hemolysis, together with ADAMTS13 activity of at least 10%. Initial authorization may be granted for 6 months; continued coverage may be authorized for 12 months when the member demonstrates a positive clinical response and has no unacceptable toxicity.

    Key Definitions

    TA-TMA
    TermTA-TMA
    DefinitionHematopoietic stem cell transplant-associated thrombotic microangiopathy.
    Covered indicationThe FDA-approved indication for Yartemlea (narsoplimab-wuug) addressed by this policy.
    ADAMTS13 Activity
    MeasurementADAMTS13 activity is a laboratory activity measurement.
    Initial approval thresholdAt least 10%.
    Coverage requirementRequired for initial approval of Yartemlea for TA-TMA.
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyYartemlea (narsoplimab-wuug) Coverage for Transplant-Associated Thrombotic Microangiopathy
    Policy CodePolicy 05.06.29
    Change TypeNo material change
    Effective DateMay 15, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization documentation confirming TA-TMA and ADAMTS13 activity for initial requests.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaCoding InformationPrior Authorization and Provider RequirementsPolicy BackgroundKey Definitions
    The member has an ADAMTS13 activity level of at least 10%.
    ≥ 10%
  1. Prohibited combination therapy: The requested medication will not be used in combination with another complement inhibitor, such as Soliris or Ultomiris, or with Defitelio (defibrotide).
  2. Required for authorization of Yartemlea for TA-TMA.
    Serum LDH
    ThresholdSerum LDH greater than the upper limit of normal (ULN)
    Clinical useEvidence of microangiopathic hemolysis for TA-TMA confirmation.
    Laboratory contextListed with schistocytes and/or low haptoglobin as evidence of microangiopathic hemolysis.
    Haptoglobin
    ThresholdHaptoglobin less than the lower limit of normal (LLN)
    Clinical useEvidence of microangiopathic hemolysis for TA-TMA confirmation.
    Laboratory contextListed with schistocytes and/or elevated serum LDH as evidence of microangiopathic hemolysis.
    • No unacceptable toxicity is present on the current regimen.
    • The member demonstrates a positive clinical response, such as improvement in platelet levels and normalization of LDH and haptoglobin levels.
    • Yartemlea will not be used with another complement inhibitor, such as Soliris or Ultomiris, or with Defitelio (defibrotide).
    • Authorization may be granted for 12 months, including for new members requesting reauthorization.
    Documentation Required

    Required Prior Authorization Documentation

    Include chart notes or medical record documentation and laboratory reports with the prior authorization request. Documentation must support the applicable initial or continuation criteria.

    • For initial requests: chart notes or medical records confirming the diagnosis of TA-TMA.
    • For initial requests: a laboratory report confirming ADAMTS13 activity.
    • For continuation requests: chart notes or medical records supporting a positive clinical response to therapy.
    Denial Risk

    Initial Approval Criteria Not Met

    An initial request does not meet approval criteria when the member is younger than 2 years or when TA-TMA is not confirmed using the required clinical and laboratory findings.

    • Member is younger than 2 years.
    • Platelet count is not < 150,000/µL.
    • Required evidence of microangiopathic hemolysis is absent, including schistocytes, elevated LDH above the ULN and/or reduced haptoglobin below the LLN.
    • ADAMTS13 activity is not ≥ 10%.
    • The requested medication will be used with another complement inhibitor or Defitelio (defibrotide).
    Denial Risk

    Continuation Criteria Not Met

    A continuation request does not meet approval criteria when the current regimen is not tolerated, there is no positive clinical response, or Yartemlea will be used with prohibited therapy.

    • Unacceptable toxicity is present while on the current regimen.
    • The member does not demonstrate a positive clinical response to therapy.
    • The requested medication will be used with another complement inhibitor, such as Soliris or Ultomiris, or with Defitelio (defibrotide).
    Denial Risk

    Criteria Not Met

    Yartemlea (narsoplimab-wuug) is not medically necessary when the member does not meet the applicable policy criteria.

    • Requests that fail the initial or continuation criteria set forth in the policy are considered not medically necessary.